

Table 19.31
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	76,239	68.6 (68.2 , 69.1)	90.0 (88.9 , 91.0)	78.6 (78.1 , 79.1)	57.7 (56.9 , 58.4)			
1 Hodgkin Lymphoma	6,826	86.4 (85.4 , 87.3)	96.0 (94.2 , 97.2)	91.5 (90.5 , 92.4)	52.7 (48.6 , 56.6)			
2 Non-Hodgkin lymphoma	67,208	67.4 (66.9 , 67.9)	88.1 (86.7 , 89.3)	76.6 (76.0 , 77.2)	58.5 (57.7 , 59.2)			
2(a) Non-Hodgkin lymphoma, B-cell	61,908	67.7 (67.2 , 68.2)	88.5 (87.0 , 89.9)	77.4 (76.7 , 78.0)	59.1 (58.3 , 59.9)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,216	67.2 (65.3 , 69.0)	88.9 (87.2 , 90.4)	35.4 (31.8 , 39.1)	11.5 (7.5 , 16.4)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	55,792	67.7 (67.2 , 68.3)	85.6 (81.2 , 89.0)	79.0 (78.3 , 79.6)	59.3 (58.5 , 60.1)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	11,796	78.4 (77.2 , 79.6)	- (- , -)	88.8 (87.4 , 90.1)	73.0 (71.3 , 74.7)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	10,736	80.7 (79.4 , 81.9)	- (- , -)	91.0 (89.5 , 92.3)	75.4 (73.5 , 77.1)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	45	28.4 (14.1 , 44.6)	- (- , -)	- (- , -)	15.6 (3.8 , 34.8)			
2(a) 2.1.3. Mantle-cell lymphoma	1,015	57.0 (52.6 , 61.1)	- (- , -)	69.5 (63.3 , 74.8)	49.4 (43.5 , 54.9)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,152	76.6 (72.4 , 80.2)	- (- , -)	85.8 (80.3 , 89.9)	71.4 (65.5 , 76.5)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	547	72.0 (65.4 , 77.5)	- (- , -)	81.5 (71.7 , 88.1)	66.9 (58.1 , 74.3)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	605	80.5 (74.8 , 85.0)	- (- , -)	89.1 (82.1 , 93.5)	75.5 (67.2 , 82.0)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	15,035	60.6 (59.6 , 61.6)	83.0 (76.8 , 87.7)	73.8 (72.5 , 75.1)	50.5 (49.1 , 52.0)			
2(a) 2.3.1. DLBCL, NOS ^c	14,846	60.3 (59.3 , 61.3)	84.6 (78.4 , 89.2)	73.6 (72.2 , 74.8)	50.5 (49.0 , 52.0)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.3. Primary effusion lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	166	84.1 (76.9 , 89.2)	- (- , -)	86.4 (78.9 , 91.3)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	589	56.8 (52.2 , 61.2)	87.9 (79.2 , 93.2)	58.7 (52.3 , 64.5)	36.3 (28.0 , 44.6)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,788	90.6 (88.9 , 92.0)	- (- , -)	94.5 (92.8 , 95.8)	87.3 (84.4 , 89.7)			
2(a) 2.5.1. Splenic MZL	403	82.5 (76.1 , 87.4)	- (- , -)	90.4 (83.1 , 94.6)	76.3 (65.2 , 84.3)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	2,937	94.8 (92.6 , 96.4)	- (- , -)	96.9 (94.9 , 98.1)	92.8 (88.6 , 95.5)			
2(a) 2.5.3. Nodal MZL	1,448	84.1 (80.7 , 86.9)	- (- , -)	89.6 (85.5 , 92.5)	80.4 (75.3 , 84.6)			
2(a) 2.6. Follicular lymphoma	9,089	86.7 (85.6 , 87.8)	- (- , -)	92.2 (91.1 , 93.2)	80.3 (78.2 , 82.3)			
2(a) 2.7. Hairy-cell leukemia	294	91.0 (83.6 , 95.2)	- (- , -)	96.6 (92.1 , 98.5)	79.0 (61.3 , 89.3)			
2(a) 2.8. Plasma cell neoplasms	13,043	43.3 (42.1 , 44.4)	- (- , -)	57.9 (56.1 , 59.6)	33.6 (32.1 , 35.1)			
2(a) 2.8.1. Plasmacytoma	686	59.0 (53.6 , 63.9)	- (- , -)	75.0 (68.3 , 80.5)	42.7 (35.0 , 50.2)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	12,357	42.4 (41.2 , 43.6)	- (- , -)	56.7 (54.8 , 58.5)	33.2 (31.7 , 34.7)			
2(a) 2.9. Heavy chain disease	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	2,900	68.3 (65.7 , 70.7)	- (- , -)	78.6 (75.3 , 81.5)	62.6 (59.0 , 66.0)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.31 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
2(b) Non-Hodgkin lymphoma, T-cell	4,161	64.5 (62.7 , 66.3)	84.9 (80.3 , 88.5)	70.5 (68.3 , 72.6)	50.5 (46.9 , 53.9)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	269	61.8 (55.1 , 67.8)	88.9 (81.0 , 93.7)	47.8 (37.9 , 57.1)	14.3 (3.7 , 31.6)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	3,851	65.2 (63.2 , 67.0)	83.3 (77.2 , 87.8)	72.2 (69.9 , 74.3)	51.7 (48.1 , 55.2)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,017	90.6 (87.2 , 93.1)	91.4 (66.2 , 98.1)	93.4 (90.1 , 95.7)	83.8 (75.1 , 89.7)			
2(b) 2.1.1. Mycosis fungoides	991	91.9 (88.6 , 94.3)	91.4 (66.2 , 98.1)	93.8 (90.5 , 96.0)	86.2 (79.2 , 90.9)			
2(b) 2.1.2. Sezary syndrome	26	33.9 (10.2 , 59.9)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2. Peripheral T-cell lymphoma	2,272	58.3 (55.8 , 60.8)	86.7 (78.0 , 92.1)	67.5 (64.4 , 70.4)	43.6 (39.4 , 47.7)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	743	38.0 (33.9 , 42.1)	- (- , -)	47.6 (41.7 , 53.4)	27.4 (21.9 , 33.2)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	339	48.7 (42.2 , 55.0)	- (- , -)	56.6 (47.4 , 64.9)	42.5 (33.3 , 51.3)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	48	61.1 (41.2 , 76.1)	- (- , -)	59.2 (32.2 , 78.5)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	441	61.2 (55.7 , 66.2)	86.6 (74.8 , 93.1)	70.5 (63.9 , 76.1)	31.4 (21.9 , 41.4)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	28	26.2 (11.0 , 44.3)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	437	81.8 (75.6 , 86.6)	- (- , -)	87.6 (81.3 , 91.9)	72.9 (60.3 , 82.0)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	222	92.2 (84.0 , 96.3)	- (- , -)	94.6 (85.7 , 98.0)	81.8 (60.4 , 92.3)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	269	47.2 (40.3 , 53.9)	78.6 (67.6 , 86.3)	32.8 (23.1 , 42.8)	25.8 (14.5 , 38.5)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	143	41.6 (31.6 , 51.3)	- (- , -)	41.2 (29.8 , 52.3)	45.3 (25.3 , 63.3)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	75	74.9 (57.1 , 86.1)	- (- , -)	77.3 (52.5 , 90.2)	69.5 (42.9 , 85.5)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	75	22.5 (11.1 , 36.4)	- (- , -)	28.4 (13.4 , 45.4)	19.5 (6.2 , 38.3)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	41	27.3 (13.4 , 43.2)	- (- , -)	40.2 (21.1 , 58.6)	- (- , -)			
2(c) Non-Hodgkin lymphoma, unknown lineage	1,139	59.8 (56.2 , 63.1)	88.2 (83.7 , 91.6)	61.1 (54.6 , 66.9)	42.8 (37.1 , 48.4)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	479	65.9 (61.2 , 70.2)	88.4 (83.8 , 91.7)	43.6 (33.1 , 53.6)	15.1 (7.2 , 25.8)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	25	60.6 (36.4 , 78.0)	- (- , -)	- (- , -)	- (- , -)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	635	54.4 (49.2 , 59.4)	- (- , -)	69.0 (60.8 , 75.9)	47.8 (41.2 , 54.1)			
2(*) 1. Total precursor lymphoma/leukemia ^d	3,964	66.7 (65.1 , 68.4)	88.9 (87.4 , 90.2)	37.7 (34.5 , 41.0)	12.4 (8.8 , 16.6)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	38	46.4 (25.6 , 64.8)	- (- , -)	- (- , -)	- (- , -)			
4 Lymphoid neoplasm, NOS ^c	2,167	48.3 (45.5 , 51.0)	86.8 (64.3 , 95.6)	65.1 (60.8 , 69.2)	39.7 (36.3 , 43.1)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.